Literature DB >> 555064

A field trial of a vaccine against American dermal leishmaniasis.

W Mayrink, C A da Costa, P A Magalhães, M N Melo, M Dias, A O Lima, M S Michalick, P Williams.   

Abstract

A field trial was carried out in the eastern part of the State of Minas Gerais (Brazil) of a vaccine containing killed promastigotes of five stocks of Leishmania. Tests with Montenegro antigen showed that a high proportion of the vaccinated persons became positive within three months, but circulating antibodies were not detected. A proportion of those vaccinated continued to give positive Montenegro reactions for up to three years. Lymphocyte sensitivity tests carried out, on a small sample, three years after vaccination were positive and gave no evidence of immunological depression. No cases of cutaneous or mucocutaneous leishmaniasis occurred in the trial area during the three years of observations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 555064     DOI: 10.1016/0035-9203(79)90159-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  22 in total

1.  Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Karla de Melo Lima; Célio Lopes Silva; José Maciel Rodrigues; Ana Paula Fernandes
Journal:  Parasitol Res       Date:  2006-01-24       Impact factor: 2.289

2.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

Review 4.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

5.  Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.

Authors:  Carmel B Stober; Selma M B Jeronimo; Nubia N Pontes; E Nancy Miller; Jenefer M Blackwell
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

Review 6.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

7.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

8.  Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant.

Authors:  J A Cook; T W Holbrook
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

9.  MPLA and AddaVax® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis.

Authors:  Diogo Oliveira-Maciel; Júlio Souza Dos-Santos; Gabriel Oliveira-Silva; Mirian França de Mello; Alessandra Marcia da Fonseca-Martins; Monique Pacheco Duarte Carneiro; Tadeu Diniz Ramos; Luan Firmino-Cruz; Daniel Claudio Oliveira Gomes; Bartira Rossi-Bergmann; Herbert Leonel de Matos Guedes
Journal:  Microorganisms       Date:  2021-06-11

10.  Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis.

Authors:  Om Prakash Singh; Carmel B Stober; Abhishek Kr Singh; Jenefer M Blackwell; Shyam Sundar
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.